Rubbing my ball, page-209

Steini's logic is correct in that MC is the only thing that ought to count, and whether it's the result of small SP x big SOI, or big SP x small SOI, should be irrelevant. But in other markets and to some extent in this one, there is a widespread perception that penny-dreadfuls are just that. US investors generally have a better appreciation of the value of biotech than Australian ones. We should want them to get interested in this stock to help the MC better reflect the real value of the company's technology and talent. I gather some board members think IMU has been held back by being listed on the ASX rather than the NASDAQ. I suspect they're right. But if we ever want US investors to get seriously interested in this stock there will have to be a consolidation, probably closer to 1:100 than 1:10, because most of them just won't look at a stock that is priced at only a few cents a share. I agree that's not logical or sensible, but it's a fact.